Ann: Travelan to progress to Phase 3 Clinical Trials in the US, page-92

The study points out that this probably means that Travellan has a GREATER effect on the more dangerous pathogens, so would be an advantatge not a disadvantage. I've cut out the comment below but of course form your own opinion. My overarching comment re this stock has always been that it is way undervalued seeing it has so much cash in the bank and is already generating revenue from sales. I'm not going to argue semantics on just how good the product is.

Studies using the CHIM for a variety of different enteric pathogens suggest the greatest protection may be againstmore severe disease and in studies where the disease appears to be predominately mild, which appears to be the casein this study, the efficacy estimates can be lower than anticipated.